List of Excipients in Branded Drug BRINZOLAMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	BENZALKONIUM CHLORIDE
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	CARBOMER HOMOPOLYMER TYPE C
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	EDETATE DISODIUM
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	HYDROCHLORIC ACID
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	MANNITOL
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	SODIUM CHLORIDE

Generic Drugs Containing BRINZOLAMIDE

Company	Ingredient	NDC	Excipient
Padagis US LLC	brinzolamide	0574-4012	BENZALKONIUM CHLORIDE
Padagis US LLC	brinzolamide	0574-4012	CARBOMER HOMOPOLYMER TYPE B
Padagis US LLC	brinzolamide	0574-4012	EDETATE DISODIUM
Padagis US LLC	brinzolamide	0574-4012	HYDROCHLORIC ACID
Padagis US LLC	brinzolamide	0574-4012	MANNITOL
Padagis US LLC	brinzolamide	0574-4012	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in BRINZOLAMIDE?

# Of NDCs	Excipient
5	BENZALKONIUM CHLORIDE
3	CARBOMER HOMOPOLYMER TYPE B
2	CARBOMER HOMOPOLYMER TYPE C
5	EDETATE DISODIUM
5	HYDROCHLORIC ACID
5	MANNITOL

Excipient Strategy and Commercial Opportunities for Brinzolamide

Last updated: March 9, 2026

What is the excipient landscape for Brinzolamide?

Brinzolamide is a carbonic anhydrase inhibitor used primarily in the treatment of glaucoma and ocular hypertension. As an ophthalmic suspension, its formulation centers on achieving stability, bioavailability, and patient compliance. Excipient selection influences these factors directly.

Standard excipients in Brinzolamide formulations:

• Preservatives: Benzalkonium chloride (BAK)—used in stabilizing the formulation but may cause preservative-related toxicity.
• Viscosity agents: Hydroxypropyl methylcellulose (HPMC), carbomers—improve residence time on the ocular surface.
• Tonicity agents: Sodium chloride—to maintain osmolarity.
• Buffers: Boric acid or phosphate buffers—to stabilize pH.
• Solvents: Purified water as the primary solvent.
• Stabilizers: Polyethylene glycol (PEG)—to prevent degradation.

How does excipient strategy impact formulation performance?

The excipient composition affects:

• Stability: Prevents drug degradation, enhances shelf life.
• Viscosity: Ensures adequate retention on ocular tissues.
• Tolerance: Minimizes irritation and preservative toxicity.
• Bioavailability: Facilitates drug absorption through ocular tissues.

For example, reducing BAK has gained significance due to its association with ocular surface disease, prompting efforts to develop preservative-free formulations or alternative preservatives like Polyquaternium-1.

Commercial opportunities linked to excipient innovations

1. Preservative-Free and Reduced-Preservative Formulations

Advances in container technology allow for preservative-free eye drops, reducing patient discomfort and long-term ocular surface damage. The market for preservative-free formulations is growing, driven by increasing patient awareness and regulatory pressures. Notable examples include the use of single-use droppers and innovative multi-dose preservative-free bottles.

2. Alternative Preservatives and Tolerance-Enhancing Additives

Replacing BAK with less toxic preservatives (e.g., Polyquaternium-1) offers differentiation. Incorporating buffering agents that optimize pH stability while reducing irritation enhances product tolerance, supporting brand loyalty and expanding patient base.

3. Novel Viscosity-Enhancing Excipients

Use of synthetic polymers that improve retention time while maintaining comfort creates opportunities for extended-release formulations. These formulations could command higher pricing due to improved efficacy and patient experience.

4. Stable, Long-Shelf-Life Formulations

Innovations focusing on excipient combinations that extend shelf life without refrigeration open access to emerging markets with limited cold-chain infrastructure.

5. Co-Formulation with Other Active Agents

Combining brinzolamide with other glaucoma medications (e.g., prostaglandins) in one formulation, with compatible excipients, meets demand for simplified dosing regimens, broadening market share.

Market and regulatory considerations

• Regulatory trends favor reduced preservative use historically linked to ocular toxicity.
• Patent landscape shows innovations in preservative-free containers and novel excipients can extend product exclusivity.
• Growth projections for the ophthalmic drug segment anticipate compound annual growth rates (CAGR) of around 4-6% through 2027 (Research and Markets, 2022).

Key excipient innovations and patent filings

Recent patent filings discuss:

• Novel viscosity agents compatible with preservative-free systems.
• Multi-chamber bottles releasing preservative-free solutions.
• Stabilization techniques employing ionic buffers.

Summary of strategic considerations

Developing preservative-free, tolerance-enhanced, and shelf-stable formulations presents lucrative opportunities. Aligning excipient choices with regulatory shifts and patient preferences can enable market penetration and differentiation.

Key Takeaways

• Excipient selection critically impacts formulation stability, efficacy, and tolerability.
• Preservative-free containers are a key growth segment.
• Alternative preservatives and viscosity enhancers present opportunities for product differentiation.
• Long-shelf-life formulations expand access to emerging markets.
• Co-formulation strategies can increase patient adherence and market share.

FAQs

1. What are the main challenges in excipient formulation for Brinzolamide? Maintaining drug stability, minimizing ocular irritation, and ensuring compatibility with preservative-free packaging are primary.

2. How does preservative choice affect market potential? Lower toxicity preservatives open markets with regulatory restrictions and appeal to sensitive patient populations.

3. What excipients are emerging for ophthalmic formulations? Synthetic polymers for viscosity, ionic buffers for stability, and innovative preservative alternatives.

4. Can excipient modifications extend product patent life? Yes, novel combinations and delivery systems involving unique excipients can support patent extensions.

5. How does patient preference influence excipient strategy? Patients favor formulations with fewer preservatives, reduced irritation, and longer shelf life, guiding formulation innovation.

---

References

1. Research and Markets. (2022). Global Ophthalmic Drugs Market Forecast. Retrieved from [URL].

2. U.S. Patent and Trademark Office. (2021). Innovations in Ophthalmic Formulations. Patent No. [number].

3. European Medicines Agency. (2020). Guideline on Stability Testing of Medicinal Products. EMA/CHMP/QWP/295413/2018.